Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.

  • Boer Den
  • [Unbekannt] Harms
  • R Pieters
  • [Unbekannt] Kazemier
  • U Gobel
  • D Körholz
  • U Graubner
  • [Unbekannt] Haas
  • N Jorch
  • [Unbekannt] Spaar
  • [Unbekannt] Kaspers
  • [Unbekannt] Kamps
  • Van der Does
  • Van den Berg
  • Van Wering
  • Gritta Janka-Schaub
  • [Unbekannt] Janka-Schaub

Abstract

PURPOSE: To confirm the prognostic value of a drug resistance profile combining prednisolone, vincristine, and l-asparaginase (PVA) cytotoxicity in an independent group of children with acute lymphoblastic leukemia (ALL) treated with a different protocol and analyzed at longer follow-up compared with our previous study of patients treated according to the Dutch Childhood Leukemia Study Group (DCLSG) ALL VII/VIII protocol. PATIENTS AND METHODS: Drug resistance profiles were determined in 202 children (aged 1 to 18 years) with newly diagnosed ALL who were treated according to the German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia (COALL)-92 protocol. RESULTS: At a median follow-up of 6.2 years (range, 4.1 to 9.3 years), the 5-year disease-free survival probability (pDFS) rate +/- SE was 69% +/- 7.0%, 83% +/- 4.4%, and 84% +/- 6.8% for patients with resistant (PVA score 7 to 9), intermediate-sensitive (PVA score 5 to 6), and sensitive (SPVA score 3 to 4) profiles, respectively (sensitive and intermediate-sensitive v resistant, P

Bibliografische Daten

OriginalspracheDeutsch
Aufsatznummer17
ISSN0732-183X
StatusVeröffentlicht - 2003
pubmed 12947061